Incidência Fiscal no Contexto de Farmácia Comunitária

Enquanto atividade profissional, a farmácia está igualmente sujeita a mecanismos fiscais, sendo que estes se encontram a cargo do contabilista da farmácia.

O IRS (Imposto sobre o Rendimento de pessoas Singulares) é o imposto que incide sobre os rendimentos das pessoas singulares ou do agregado familiar, caso exista. De entre os produtos de venda ao público na farmácia, os produtos com IVA a 6% podem todos entrar para os encargos, enquanto os produtos com IVA a 23% apenas podem ser deduzidos caso tenham a respetiva receita médica anexada.

O IVA (Imposto sobre o Valor Acrescentado) é pago pelo consumidor final, o utente. A farmácia paga o IVA dos produtos aos fornecedores, no entanto este também é pago pelos utentes no ato de venda. No final de cada trimestre, ou ano, a farmácia faz o balanço do IVA recebido pelos utentes e do IVA pago aos fornecedores, sendo que, se este balanço for positivo, a farmácia terá de devolver ao Estado o valor do IVA em excesso mas, pelo contrário, se o balanço for negativo, o Estado reembolsa a diferença em falta.

O IRC é o imposto de rendimento de pessoas coletivas e é calculado com base no rendimento gerado pela farmácia durante o ano.

13.

CONCLUSÃO

O estágio em Farmácia Comunitária demonstrou-me a lacuna que permanece depois de cinco anos em Ciências Farmacêuticas. A transposição dos conhecimentos adquiridos na faculdade não se apresenta de uma forma tão linear como expectável. O contacto com a organização dos medicamentos por nome comercial, a manipulação do sistema de gestão de todo o ciclo do medicamento na farmácia bem como a comunicação com os utentes foram pontos com os quais, de início, estava pouco à vontade no exercício da minha atividade enquanto estagiária, pelo que o apoio de toda a equipa foi crucial para solucionar alguns dos problemas com os quais me deparei.

mais vincadamente que a formação contínua é extremamente necessária e não deve ser dispensada por nenhum profissional da área da saúde.

REFERÊNCIAS BIBLIOGRÁFICAS

1.

Ivashkiv LB, Hu X. The JAK/STAT pathway in rheumatoid arthritis: pathogenic or

protective? Arthritis Rheum. 2003 Aug;48(8):2092-6.

2.

Ghoreschi K, Gadina M. Jakpot! New small molecules in autoimmune and

inflammatory diseases. Exp Dermatol. 2014 Jan;23(1):7-11.

3.

Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, et al. Activating

mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and

myeloid metaplasia with myelofibrosis. Cancer Cell. 2005 Apr;7(4):387-97.

4.

Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, et al. A gain-of-

function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005 Apr

28;352(17):1779-90.

5.

Cascavilla N, De Stefano V, Pane F, Pancrazzi A, Iurlo A, Gobbi M, et al. Impact of

JAK2(V617F) mutation status on treatment response to anagrelide in essential

thrombocythemia: an observational, hypothesis-generating study. Drug Des Devel Ther.

2015;9:2687-94.

6.

Kleppe M, Kwak M, Koppikar P, Riester M, Keller M, Bastian L, et al. JAK-STAT pathway

activation in malignant and nonmalignant cells contributes to MPN pathogenesis and

therapeutic response. Cancer Discov. 2015 Mar;5(3):316-31.

7.

Guglielmelli P, Biamonte F, Rotunno G, Artusi V, Artuso L, Bernardis I, et al. Impact of

mutational status on outcomes in myelofibrosis patients treated with ruxolitinib in the

COMFORT-II study. Blood. 2014 Apr 3;123(14):2157-60.

8.

Vicente C, Schwab C, Broux M, Geerdens E, Degryse S, Demeyer S, et al. Targeted

sequencing identifies associations between IL7R-JAK mutations and epigenetic modulators in

T-cell acute lymphoblastic leukemia. Haematologica. 2015 Oct;100(10):1301-10.

9.

Deininger M, Radich J, Burn TC, Huber R, Paranagama D, Verstovsek S. The effect of

long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis.

Blood. 2015 Sep 24;126(13):1551-4.

10.

Roncero AM, Lopez-Nieva P, Cobos-Fernandez MA, Villa-Morales M, Gonzalez-Sanchez

L, Lopez-Lorenzo JL, et al. Contribution of JAK2 mutations to T-cell lymphoblastic lymphoma

development. Leukemia. 2016 Jan;30(1):94-103.

11.

Russell LJ, Capasso M, Vater I, Akasaka T, Bernard OA, Calasanz MJ, et al. Deregulated

expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell

precursor acute lymphoblastic leukemia. Blood. 2009 Sep 24;114(13):2688-98.

12.

Lacronique V, Boureux A, Monni R, Dumon S, Mauchauffe M, Mayeux P, et al.

Transforming properties of chimeric TEL-JAK proteins in Ba/F3 cells. Blood. 2000 Mar

15;95(6):2076-83.

13.

Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, et al. JAK

inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012

Mar 1;366(9):787-98.

14.

Lee EB, Fleischmann R, Hall S, Wilkinson B, Bradley JD, Gruben D, et al. Tofacitinib

versus methotrexate in rheumatoid arthritis. N Engl J Med. 2014 Jun 19;370(25):2377-86.

15.

Mesa RA, Kiladjian JJ, Verstovsek S, Al-Ali HK, Gotlib J, Gisslinger H, et al. Comparison of

placebo and best available therapy for the treatment of myelofibrosis in the phase 3 COMFORT

studies. Haematologica. 2014 Feb;99(2):292-8.

16.

EMA. Resumo das Características do Medicamento Jakavi. of issue of marketing

authorisation valid throughout the European Union23/08/2012 [cited; Acess Date:

12/09/2015].

Available

from:

http://www.ema.europa.eu/docs/pt_PT/document_library/EPAR_-

_Product_Information/human/002464/WC500133223.pdf

17.

FDA US. HIGHLIGHTS OF PRESCRIBING INFORMATION. 2016 [cited; Acess Date:

12/09/2015].

Available

from:

http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208246s000lbl.pdf

18.

Administration USFaD. HIGHLIGHTS OF PRESCRIBING INFORMATION. 2016 [cited;

Acess

Date:

12/09/2015].

Available

from:

http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202192lbl.pdf

19.

Agency EM. EPAR summary for the public. Jakavi. of issue of marketing authorisation

valid throughout the European Union23/08/2012 [cited Acess Date: 13/06/2015]; Available

from:

http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-

_Summary_for_the_public/human/002464/WC500133225.pdf

22.

Mesa RA, Verstovsek S, Gupta V, Mascarenhas JO, Atallah E, Burn T, et al. Effects of

ruxolitinib treatment on metabolic and nutritional parameters in patients with myelofibrosis

from COMFORT-I. Clin Lymphoma Myeloma Leuk. 2015 Apr;15(4):214-21.e1.

23.

Geyer H, Scherber R, Kosiorek H, Dueck AC, Kiladjian JJ, Xiao Z, et al. Symptomatic

Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease. J

Clin Oncol. 2016 Jan 10;34(2):151-9.

24.

Vannucchi AM. Ruxolitinib versus standard therapy for the treatment of polycythemia

vera. N Engl J Med. 2015 Apr 23;372(17):1670-1.

25.

Verstovsek S, Passamonti F, Rambaldi A, Barosi G, Rosen PJ, Rumi E, et al. A phase 2

study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia

vera who are refractory or intolerant to hydroxyurea. Cancer. 2014 Feb 15;120(4):513-20.

26.

Schonberg K, Rudolph J, Vonnahme M, Parampalli Yajnanarayana S, Cornez I, Hejazi M,

et al. JAK Inhibition Impairs NK Cell Function in Myeloproliferative Neoplasms. Cancer Res.

2015 Jun 1;75(11):2187-99.

27.

Wathes R, Moule S, Milojkovic D. Progressive multifocal leukoencephalopathy

associated with ruxolitinib. N Engl J Med. 2013 Jul 11;369(2):197-8.

28.

Lee SC, Feenstra J, Georghiou PR. Pneumocystis jiroveci pneumonitis complicating

ruxolitinib therapy. BMJ Case Rep. 2014;2014.

29.

Song GG, Bae SC, Lee YH. Efficacy and safety of tofacitinib for active rheumatoid

arthritis with an inadequate response to methotrexate or disease-modifying antirheumatic

drugs: a meta-analysis of randomized controlled trials. Korean J Intern Med. 2014

Sep;29(5):656-63.

30.

Migita K, Izumi Y, Jiuchi Y, Kozuru H, Kawahara C, Izumi M, et al. Effects of Janus kinase

inhibitor tofacitinib on circulating serum amyloid A and interleukin-6 during treatment for

rheumatoid arthritis. Clin Exp Immunol. 2014 Feb;175(2):208-14.

31.

Dowty ME, Jesson MI, Ghosh S, Lee J, Meyer DM, Krishnaswami S, et al. Preclinical to

clinical translation of tofacitinib, a Janus kinase inhibitor, in rheumatoid arthritis. J Pharmacol

Exp Ther. 2014 Jan;348(1):165-73.

32.

Boyle DL, Soma K, Hodge J, Kavanaugh A, Mandel D, Mease P, et al. The JAK inhibitor

tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis. Ann Rheum Dis.

2015 Jun;74(6):1311-6.

33.

Fleischmann R, Kremer J, Cush J, Schulze-Koops H, Connell CA, Bradley JD, et al.

Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012

Aug 9;367(6):495-507.

34.

van Vollenhoven RF, Fleischmann R, Cohen S, Lee EB, Garcia Meijide JA, Wagner S, et

al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012 Aug

9;367(6):508-19.

35.

Wollenhaupt J, Silverfield J, Lee EB, Curtis JR, Wood SP, Soma K, et al. Safety and

efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis

in open-label, longterm extension studies. J Rheumatol. 2014 May;41(5):837-52.

36.

Charles-Schoeman C, Fleischmann R, Davignon J, Schwartz H, Turner SM, Beysen C, et

al. Potential mechanisms leading to the abnormal lipid profile in patients with rheumatoid

arthritis versus healthy volunteers and reversal by tofacitinib. Arthritis Rheumatol. 2015

Mar;67(3):616-25.

37.

Kremer JM, Kivitz AJ, Simon-Campos JA, Nasonov EL, Tony HP, Lee SK, et al. Evaluation

of the effect of tofacitinib on measured glomerular filtration rate in patients with active

rheumatoid arthritis: results from a randomised controlled trial. Arthritis Res Ther. 2015;17:95.

38.

Sonomoto K, Yamaoka K, Kubo S, Hirata S, Fukuyo S, Maeshima K, et al. Effects of

tofacitinib on lymphocytes in rheumatoid arthritis: relation to efficacy and infectious adverse

events. Rheumatology (Oxford). 2014 May;53(5):914-8.

39.

Piscianz E, Valencic E, Cuzzoni E, De Iudicibus S, De Lorenzo E, Decorti G, et al. Fate of

lymphocytes after withdrawal of tofacitinib treatment. PLoS One. 2014;9(1):e85463.

40.

Gonzales AJ, Bowman JW, Fici GJ, Zhang M, Mann DW, Mitton-Fry M. Oclacitinib

(APOQUEL((R))) is a novel Janus kinase inhibitor with activity against cytokines involved in

allergy. J Vet Pharmacol Ther. 2014 Aug;37(4):317-24.

41.

Fleischmann RM, Damjanov NS, Kivitz AJ, Legedza A, Hoock T, Kinnman N. A

randomized, double-blind, placebo-controlled, twelve-week, dose-ranging study of

decernotinib, an oral selective JAK-3 inhibitor, as monotherapy in patients with active

rheumatoid arthritis. Arthritis Rheumatol. 2015 Feb;67(2):334-43.

42.

Mahajan S, Hogan JK, Shlyakhter D, Oh L, Salituro FG, Farmer L, et al. VX-509

(decernotinib) is a potent and selective janus kinase 3 inhibitor that attenuates inflammation

in animal models of autoimmune disease. J Pharmacol Exp Ther. 2015 May;353(2):405-14.

43.

Namour F, Diderichsen PM, Cox E, Vayssiere B, Van der Aa A, Tasset C, et al.

Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634),

45.

Fridman JS, Scherle PA, Collins R, Burn TC, Li Y, Li J, et al. Selective inhibition of JAK1

and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of

INCB028050. J Immunol. 2010 May 1;184(9):5298-307.

46.

Genovese MC, Kremer J, Zamani O, Ludivico C, Krogulec M, Xie L, et al. Baricitinib in

Patients with Refractory Rheumatoid Arthritis. N Engl J Med. 2016 Mar 31;374(13):1243-52.

47.

Pardanani A, Tefferi A, Jamieson C, Gabrail NY, Lebedinsky C, Gao G, et al. A phase 2

randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in

patients with myelofibrosis. Blood Cancer J. 2015;5:e335.

48.

Zhang Q, Zhang Y, Diamond S, Boer J, Harris JJ, Li Y, et al. The Janus kinase 2 inhibitor

fedratinib inhibits thiamine uptake: a putative mechanism for the onset of Wernicke's

encephalopathy. Drug Metab Dispos. 2014 Oct;42(10):1656-62.

49.

Jamieson C, Hasserjian R, Gotlib J, Cortes J, Stone R, Talpaz M, et al. Effect of treatment

with a JAK2-selective inhibitor, fedratinib, on bone marrow fibrosis in patients with

myelofibrosis. J Transl Med. 2015;13:294.

50.

Meyer SC, Keller MD, Chiu S, Koppikar P, Guryanova OA, Rapaport F, et al. CHZ868, a

Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in

Myeloproliferative Neoplasms. Cancer Cell. 2015 Jul 13;28(1):15-28.

51.

Pardanani A, Laborde RR, Lasho TL, Finke C, Begna K, Al-Kali A, et al. Safety and efficacy

of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis. Leukemia. 2013 Jun;27(6):1322-7.

52.

Hexner E, Roboz G, Hoffman R, Luger S, Mascarenhas J, Carroll M, et al. Open-label

study of oral CEP-701 (lestaurtinib) in patients with polycythaemia vera or essential

thrombocythaemia with JAK2-V617F mutation. Br J Haematol. 2014 Jan;164(1):83-93.

53.

Degryse S, Cools J. JAK kinase inhibitors for the treatment of acute lymphoblastic

leukemia. J Hematol Oncol. 2015;8:91.

54.

Coffey G, Betz A, DeGuzman F, Pak Y, Inagaki M, Baker DC, et al. The novel kinase

inhibitor PRT062070 (Cerdulatinib) demonstrates efficacy in models of autoimmunity and B-

cell cancer. J Pharmacol Exp Ther. 2014 Dec;351(3):538-48.

55.

Wu SC, Li LS, Kopp N, Montero J, Chapuy B, Yoda A, et al. Activity of the Type II JAK2

Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia. Cancer Cell. 2015 Jul 13;28(1):29-41.

56.

Suryani S, Bracken LS, Harvey RC, Sia KC, Carol H, Chen IM, et al. Evaluation of the in

vitro and in vivo efficacy of the JAK inhibitor AZD1480 against JAK-mutated acute

lymphoblastic leukemia. Mol Cancer Ther. 2015 Feb;14(2):364-74.

57.

Xing L, Dai Z, Jabbari A, Cerise JE, Higgins CA, Gong W, et al. Alopecia areata is driven

by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med. 2014 Sep;20(9):1043-9.

58.

Blume-Peytavi U, Vogt A. Translational Positioning of Janus Kinase (JAK) Inhibitors in

Alopecia Areata. EBioMedicine. 2015 Apr;2(4):282-3.

59.

Jabbari A, Dai Z, Xing L, Cerise JE, Ramot Y, Berkun Y, et al. Reversal of Alopecia Areata

Following Treatment With the JAK1/2 Inhibitor Baricitinib. EBioMedicine. 2015 Apr;2(4):351-5.

60.

Gu L, Talati P, Vogiatzi P, Romero-Weaver AL, Abdulghani J, Liao Z, et al. Pharmacologic

suppression of JAK1/2 by JAK1/2 inhibitor AZD1480 potently inhibits IL-6-induced experimental

prostate cancer metastases formation. Mol Cancer Ther. 2014 May;13(5):1246-58.

61.

Maenhout SK, Du Four S, Corthals J, Neyns B, Thielemans K, Aerts JL. AZD1480 delays

tumor growth in a melanoma model while enhancing the suppressive activity of myeloid-

derived suppressor cells. Oncotarget. 2014 Aug 30;5(16):6801-15.

62.

Wang SW, Hu J, Guo QH, Zhao Y, Cheng JJ, Zhang DS, et al. AZD1480, a JAK inhibitor,

inhibits cell growth and survival of colorectal cancer via modulating the JAK2/STAT3 signaling

pathway. Oncol Rep. 2014 Nov;32(5):1991-8.

63.

Houghton PJ, Kurmasheva RT, Lyalin D, Maris JM, Kolb EA, Gorlick R, et al. Initial solid

tumor testing (stage 1) of AZD1480, an inhibitor of Janus kinases 1 and 2 by the pediatric

preclinical testing program. Pediatr Blood Cancer. 2014 Nov;61(11):1972-9.

64.

Nagaraju GP, Mezina A, Shaib WL, Landry J, El-Rayes BF. Targeting the Janus-activated

kinase-2-STAT3 signalling pathway in pancreatic cancer using the HSP90 inhibitor ganetespib.

Eur J Cancer. 2016 Jan;52:109-19.

65.

Sagawa M, Tabayashi T, Kimura Y, Tomikawa T, Nemoto-Anan T, Watanabe R, et al.

TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by

inhibiting both JAK/STAT and proteasome activities. Cancer Sci. 2015 Apr;106(4):438-46.

66.

Ashino S, Takeda K, Li H, Taylor V, Joetham A, Pine PR, et al. Janus kinase 1/3 signaling

pathways are key initiators of TH2 differentiation and lung allergic responses. J Allergy Clin

Immunol. 2014 Apr;133(4):1162-74.

67.

Amano W, Nakajima S, Kunugi H, Numata Y, Kitoh A, Egawa G, et al. The Janus kinase

inhibitor JTE-052 improves skin barrier function through suppressing signal transducer and

activator of transcription 3 signaling. J Allergy Clin Immunol. 2015 Sep;136(3):667-77.e7.

68.

Tanimoto A, Ogawa Y, Oki C, Kimoto Y, Nozawa K, Amano W, et al. Pharmacological

properties of JTE-052: a novel potent JAK inhibitor that suppresses various inflammatory

70.

Park JS, Lee J, Lim MA, Kim EK, Kim SM, Ryu JG, et al. JAK2-STAT3 blockade by AG490

suppresses autoimmune arthritis in mice via reciprocal regulation of regulatory T Cells and

Th17 cells. J Immunol. 2014 May 1;192(9):4417-24.

71.

Gurbuz V, Konac E, Varol N, Yilmaz A, Gurocak S, Menevse S, et al. Effects of AG490

and S3I-201 on regulation of the JAK/STAT3 signaling pathway in relation to angiogenesis in

TRAIL-resistant prostate cancer cells in vitro. Oncol Lett. 2014 Mar;7(3):755-63.

72.

Mohan CD, Bharathkumar H, Bulusu KC, Pandey V, Rangappa S, Fuchs JE, et al.

Development of a novel azaspirane that targets the Janus kinase-signal transducer and

activator of transcription (STAT) pathway in hepatocellular carcinoma in vitro and in vivo. J Biol

Chem. 2014 Dec 5;289(49):34296-307.

73.

Hamasaki M, Hideshima T, Tassone P, Neri P, Ishitsuka K, Yasui H, et al. Azaspirane (N-

N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple

myeloma cell growth in the bone marrow milieu in vitro and in vivo. Blood. 2005 Jun

1;105(11):4470-6.

74.

Nakaya Y, Shide K, Naito H, Niwa T, Horio T, Miyake J, et al. Effect of NS-018, a selective

JAK2V617F inhibitor, in a murine model of myelofibrosis. Blood Cancer J. 2014;4:e174.

75.

Yamamoto Y, De Velasco MA, Kura Y, Nozawa M, Hatanaka Y, Oki T, et al. Evaluation of

in vivo responses of sorafenib therapy in a preclinical mouse model of PTEN-deficient of

prostate cancer. J Transl Med. 2015;13:150.

76.

Cheppudira BP, Garza TH, Petz LN, Clifford JL, Fowler M. Anti-hyperalgesic effects of

AG490, a Janus kinase inhibitor, in a rat model of inflammatory pain. Biomed Rep. 2015

Sep;3(5):703-6.

77.

Panes J, Su C, Bushmakin AG, Cappelleri JC, Mamolo C, Healey P. Randomized trial of

tofacitinib in active ulcerative colitis: analysis of efficacy based on patient-reported outcomes.

BMC Gastroenterol. 2015;15:14.

78.

Sandborn WJ, Ghosh S, Panes J, Vranic I, Su C, Rousell S, et al. Tofacitinib, an oral Janus

kinase inhibitor, in active ulcerative colitis. N Engl J Med. 2012 Aug 16;367(7):616-24.

79.

Valenzuela F, Papp KA, Pariser D, Tyring SK, Wolk R, Buonanno M, et al. Effects of

tofacitinib on lymphocyte sub-populations, CMV and EBV viral load in patients with plaque

psoriasis. BMC Dermatol. 2015;15:8.

80.

Bushmakin AG, Mamolo C, Cappelleri JC, Stewart M. The relationship between pruritus

and the clinical signs of psoriasis in patients receiving tofacitinib. J Dermatolog Treat. 2015

Feb;26(1):19-22.

81.

Gao W, McGarry T, Orr C, McCormick J, Veale DJ, Fearon U. Tofacitinib regulates

synovial inflammation in psoriatic arthritis, inhibiting STAT activation and induction of negative

feedback inhibitors. Ann Rheum Dis. 2016 Jan;75(1):311-5.

82.

Zhang M, Mathews Griner LA, Ju W, Duveau DY, Guha R, Petrus MN, et al. Selective

targeting of JAK/STAT signaling is potentiated by Bcl-xL blockade in IL-2-dependent adult T-cell

leukemia. Proc Natl Acad Sci U S A. 2015 Oct 6;112(40):12480-5.

83.

Maude SL, Dolai S, Delgado-Martin C, Vincent T, Robbins A, Selvanathan A, et al.

Efficacy of JAK/STAT pathway inhibition in murine xenograft models of early T-cell precursor

(ETP) acute lymphoblastic leukemia. Blood. 2015 Mar 12;125(11):1759-67.

84.

An HJ, Choi EK, Kim JS, Hong SW, Moon JH, Shin JS, et al. INCB018424 induces

apoptotic cell death through the suppression of pJAK1 in human colon cancer cells.

Neoplasma. 2014;61(1):56-62.

85.

Tsirigotis P, Papanikolaou N, Elefanti A, Konstantinou P, Gkirkas K, Rontogianni D, et al.

Treatment of Experimental Candida Sepsis with a Janus Kinase Inhibitor Controls Inflammation

and Prolongs Survival. Antimicrob Agents Chemother. 2015 Dec;59(12):7367-73.

86.

Chan ES, Herlitz LC, Jabbari A. Ruxolitinib Attenuates Cutaneous Lupus Development in

a Mouse Lupus Model. J Invest Dermatol. United States; 2015. p. 1912-5.

87.

Hurwitz HI, Uppal N, Wagner SA, Bendell JC, Beck JT, Wade SM, 3rd, et al. Randomized,

Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in

Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed. J

Clin Oncol. 2015 Dec 1;33(34):4039-47.

88.

Pemmaraju N, Kantarjian H, Kadia T, Cortes J, Borthakur G, Newberry K, et al. A phase

I/II study of the Janus kinase (JAK)1 and 2 inhibitor ruxolitinib in patients with relapsed or

refractory acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2015 Mar;15(3):171-6.

89.

Gavegnano C, Detorio M, Montero C, Bosque A, Planelles V, Schinazi RF. Ruxolitinib

and tofacitinib are potent and selective inhibitors of HIV-1 replication and virus reactivation in

vitro. Antimicrob Agents Chemother. 2014;58(4):1977-86.

90.

Fukuyama T, Ehling S, Cook E, Baumer W. Topically Administered Janus-Kinase

Inhibitors Tofacitinib and Oclacitinib Display Impressive Antipruritic and Anti-Inflammatory

Responses in a Model of Allergic Dermatitis. J Pharmacol Exp Ther. 2015 Sep;354(3):394-405.

93.

Conselho Executivo da Farmácia Hospitalar. Manual de Farmácia Hospitalar. março de

2008

[cited;

Acedido

em

30/08/2016].

Available

from:

http://www.infarmed.pt/portal/page/portal/INFARMED/PUBLICACOES/TEMATICOS/MANUAL_

FARMACIA_HOSPITALAR/manual.pdf

94.

Decreto Regulamentar nº 61/94, de 12 de outubro - Regulamenta o Decreto-Lei n.º

15/93, de 22 de janeiro. INFARMED ‐ Gabinete Jurídico e Contencioso.

95.

Despacho n.º 2061-C/2013, de 1 de fevereiro - Cria a Comissão Nacional de Farmácia e

Terapêutica e estabelece as suas competências e composição. INFARMED ‐ Gabinete Jurídico e

Contencioso.

96.

Decreto‐Lei n.º 176/2006, de 30 de Agosto - Estatuto do Medicamento. INFARMED -

Gabinete Jurídico e Contencioso.

97.

Deliberação n.º 105/CA/2007, de 1 de março - Regulamento sobre Autorizações de

Utilização Especial e Excepcional de Medicamentos. INFARMED - Gabinete Jurídico e

Contencioso.

98.

INFARMED. Circular Informativa N.º 01/CD/2012 - Procedimentos de cedência de

medicamentos no ambulatório hospitalar. 2012.

99.

INFARMED. Medicamentos comparticipados de dispensa exclusiva em Farmácia

Hospitalar.

2016

[cited;

Access

Date:

02//2016].

Available

from:

http://www.infarmed.pt/portal/page/portal/INFARMED/MEDICAMENTOS_USO_HUMANO/AV

ALIACAO_ECONOMICA_E_COMPARTICIPACAO/MEDICAMENTOS_USO_AMBULATORIO/MEDIC

AMENTOS_COMPARTICIPADOS/Dispensa_exclusiva_em_Farmacia_Hospitalar

100.

Lei n.º 21/2014, de 16 de abril - Aprova a lei da investigação clínica.

INFARMED ‐ Gabinete Jurídico e Contencioso.

101.

Conselho Nacional da Qualidade. Ordem dos Farmacêuticos. Boas Práticas

Farmacêuticas para a farmácia comunitária (BPF); 3ª ed. 2009.

102.

Portaria nº 277/2012, de 12 de setembro - Define o horário padrão de funcionamento

das farmácias de oficina, regula o procedimento de aprovação e a duração, execução,

divulgação e fiscalização das escalas de turnos, bem como o valor máximo a cobrar pelas

farmácias de turno pela dispensa de medicamentos não prescritos em receita médica do

próprio dia ou do dia anterior, e revoga a Portaria n.º 31-A/2011, de 11 de janeiro. INFARMED

- Gabinete Jurídico e Contencioso.

103.

Portaria n.º 14/2013, de 11 de janeiro - Primeira alteração à Portaria n.º 277/2012, de

12 de setembro, que define o horário padrão de funcionamento das farmácias de oficina,

regula o procedimento de aprovação e a duração, execução, divulgação e fiscalização das

escalas de turnos, bem como o valor máximo a cobrar pelas farmácias de turno pela dispensa

de medicamentos não prescritos em receita médica do próprio dia ou do dia anterior.

INFARMED - Gabinete Jurídico e Contencioso.

104.

Decreto-Lei n.º 307/2007, de 31 de Agosto - Regime jurídico das farmácias de oficina.

INFARMED ‐ Gabinete Jurídico e Contencioso.

105.

Decreto-Lei n.º 171/2012, de 1 de agosto - Procede à segunda alteração ao Decreto-Lei

n.º 307/2007, de 31 de agosto, que estabelece o regime jurídico das farmácias de oficina.

INFARMED - Gabinete Jurídico e Contencioso.

106.

Deliberação n.º 1502/2014, de 3 de julho - Regulamentação das áreas mínimas das

farmácias, de acordo com n.os 4 e 5 do artigo 29.º e do artigo 57.º-A do Decreto-Lei n.º

No documento Inibidores das Janus Associated Kinases na Terapêutica Farmacológica (páginas 84-97)